This same study compared the effectivenessof BRD4 inhibitors JQ1and I-BET762, dual-ERK5-BRD4 inhibitors including XMD8-92 (5), and the ERK5-selective inhibitor AX15836 (7) in inhibitingproliferation of the acute myeloid leukemia MV-4-11, which containsa mutation reported to lead to constitutive activation of ERK5. This evidence concerns the gene MAPK7 and acute myeloid leukemia.